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Review Article
Abstract
This review article examines 1,368 publications on prostate cancer in India, as covered in Scopus database during 2004-13, ex-
periencing an annual average growth rate of 18.77% and citation impact of 5.23. The world prostate cancer output (89,994 pub-
lications) came from several countries, of which the top 15 (United States, United Kingdom, Germany, Canada, Italy, Japan, and
China) accounts for 94.80% share of the global output during 2004-13. India’s global publication share was 1.52% and hold 14th
rank in global publication output during 2004-13. The Indian prostate cancer output came from several organizations and au-
thors, of which the top 20 and 19 contributed 41.81% and 24.05% share, respectively, during 2004-13. India’s international
collaborative share in prostate cancer was 23.39%, which decreased from 24.42% to 22.98% from 2004-08 to 2009-13. Medicine
accounted for the largest share (59.50%) of output in prostate cancer followed by biochemistry, genetics and molecular biology
(40.13%), pharmacology, toxicology & pharmaceutics (27.63%), chemistry (8.55%), agricultural and biological sciences (4.31%
share), and immunology and microbiology (2.70% share) during 2004-13. Diagnosis, screening, chemotherapy, radiotherapy,
pathology and prognosis together account for 60.24% publications share among treatments methods used in Indian prostate
cancer research during 2004-13. Only Delhi, Maharashtra, Uttar Pradesh and Tamil Nadu together contributed 57.82% share in
Indian publications output in prostate cancer during 2004-13. The authors stressed the need for developing national policy for
prostate cancer which should take care of screening for detection and diagnosis, management and treatment options of the
prostate cancer patients in India.
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Introduction
The prostate gland is part of a man's reproductive and uri-
nary systems. It is oval shaped with a rounded tip and its size
varies (with age) from the size of a walnut to a small apple.
The prostate surrounds the base (or neck) of the bladder. It
has 2 lobes that surround the urethra. The urethra carries
urine from the bladder, through the prostate, and out the
penis. The prostate gland is covered in a layer of connective
tissue called the prostatic capsule and is made up of different
types of cells: (i) gland cells that produce the fluid portion of
semen, (ii) muscle cells that control urine flow and ejacula-
tion and (iii) fibrous cells that provide the supportive struc-
ture of the gland. Around the prostate, there are structures:
(i) seminal vesicles - these glands produce semen and are
found on both sides of the prostate, (ii) vas deferens – these
tubes carry sperm from the testicles to the seminal vesicles,
(iii) nerve bundles - these nerves control bladder and erectile
function and are found on both sides of the prostate and (iv)
muscles -these muscles control urination.1
The prostate gland is divided into three zones: (i) peripheral
zone- it is the largest part of prostate and closest to the rec-
tum. This zone accounts for approximately 75% the prostate
tumors (approximately 75%); (ii) transition zone - a middle
area of the prostate (about 20% of the prostate gland) and
surrounds the urethra as it passes through the prostate; and
(iii) central zone- The area in front of the transition zone of
the prostate and is farthest from the rectum. The main func-
tion of the prostate is to produce the fluid portion of semen.
A thin fluid (made continuously) rich in proteins and miner-
als that maintain and nourish sperm is produced by the gland
cells within the prostate. When a man is sexually aroused,
the prostate produces larger amounts of this fluid. It then
mixes with sperm and is ejaculated as semen. However, its
excess production passes from the body to the urine. The
prostate also plays a part in controlling the flow of urine.
The urethra runs from the bladder, through the prostate, and
out through the penis. The muscle fibers of the prostate are
wrapped around the urethra and are under involuntary
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nervous system control. These fibers contract to slow and
stop the flow of urine.1 Prostate cancer starts in the cells of
the prostate several types of cells are found in the prostate,
but almost all prostate cancers develop from the gland cells.
Gland cells make the prostate fluid that is added to the se-
men. The cancer that starts in gland cells is called isadeno-
carcinoma. Other rare types of cancer can also start in the
prostate gland, including sarcomas, small cell carcinomas,
and transitional cell carcinomas.2
Prostate cancer is the second most common cancer (with
15% of all cancer cases) in men, with an estimated 1.1 mil-
lion cases (developed region -759,000 cases, developing re-
gions - 353,000, India-19,000) is diagnosed in 2012. The
prostate cancer incidence varies across different geographical
regions. It is very high in developed regions such as Austral-
ia/New Zealand and North America (Age Standardized Rates
(ASR) 111.6 and 97.2 per 100,000 respectively). It is high in
terms of Age Standarized Rates in few developed regions
such as Caribbean (79.8), South Africa (61.8) and South
America (60.1) and low in Asian region with estimated rates
of 10.5 and 4.5 in Eastern and South Central Asia. With an
estimated 307,000 deaths (developed regions-142,000, de-
veloping regions-165,000 and India-12,000) in 2012, prostate
cancer is the fifth leading cause of death from cancer in men
(6.6% of the total men deaths). Mortality rates in terms of
Age Standarized Rates are observed generally high in pre-
dominantly black population (Caribbean, 20 per 100,000),
Sub-Saharan Africa (ASRs 19-24 per 100,000), very low in
Asia (2.9 per 100,000 in South Central Asia) and intermedi-
ate in the Americas and Oceania.3
In the past, there are no specific studies on the scientometric
analysis of prostate cancer research both at global and na-
tional level. However, only few studies have been undertaken
in the past on the contribution, citation impact, and evalua-
tion of Indian cancer literature. Among such quantitative
studies, Patra and Bhattacharya 4 had analyzed World and
Indian oncology research output during 1987-2003, using
PubMed database. It studied research output and global con-
tribution of different countries in world output. It mainly
studied India’s cancer literature growth trends and explored
the application of Bradford’s Law of Scattering for identifying
core journals and Lotka’s Law for author productivity in
Indian literature. It also identified the most active Indian
institutions involved in cancer research. Lewison and Roe 5
undertook a comprehensive study on Indian cancer research
output during 1990-2010. It focused on Indian cancer litera-
ture, its growth, research impact, international collaborative
publications share, publication output by geographical areas
and, type of research, publication output by cancer site or
manifestation and sources of funding for Indian research. The
authors observed that distribution of Indian research by
cancer site correlates positively with the relative disease
burden. Basu, Roe and Lewison 6 studied the Canada and USA
settled (NRIs) Indian origin scholars in the field of cancer
during three periods: 1988-90, 1998-2000 and 2008-10. Sev-
eral authors have examined Indian research publications
output in bone marrow research, oral cancer 8 and cervical
cancer 9 and lymphoma cancer 10. These publications  have
examined the literature growth, citation impact and global
share, the contribution by sub-fields, type of research, cancer
site, treatment methods and population age groups, contri-
bution by type of Indian organization and geographical dis-
tribution, contribution and citation impact of top organiza-
tions and authors and pattern of communication. Keyan et al.
11 examined the articles in 39 issues of Indian Journal of
Cancer during 2003-12. It studied the literature growth,
author productivity, authorship pattern, average length of
articles and country collaboration of cancer research in India.
The main objectives of this study are to study the perfor-
mance of Indian research in prostate cancer during 2004-13,
based on publications output, as indexed in Scopus database.
In particular, the study focuses on the following objectives to
study
 Growth of world and Indian research output by
type of publication;
 Citation pattern of the Indian research output;
 Contribution, global publication share and citation
impact of top 15 most productive countries;
 International collaboration share of publication of
top 15 most productive countries and the extent of
inter-country collaborative linkages among them
and to identify the leading collaborative partners
and their share in India’s output;
 Distribution of Indian research output by broad
subject areas and study their growth and decline;
 Indian prostate cancer output by treatment methods
and their distribution by geographical areas;
 Publication productivity and citation impact of
most productive twenty Indian institutions and
nineteen authors; and
 Leading media of communication
Literature search
The study retrieved and downloaded the publication data of
the world and of 15 most productive countries in prostate
cancer from the Scopus database (http://www.scopus.com) for
10 years during 2004-13. The keyword “prostate cancer” and
“cancer or neoplasm or carcinoma” were used in “title, ab-
stract and keyword” tag and restricting it to the period
2004-13 in “date range tag” was used for searching the global
publication data and this become the main search string.
When the main search string with restricted to 15 most
productive countries in “country tag”, as shown below, the
publication data on productive countries were obtained.
When the main search string is further restricted to “subject
area tag”, “country tag”, “source title tag”, “journal title name”
and “affiliation tag”, we got information on distribution of
publications by subject, collaborating countries, organiza-
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tion-wise and journal-wise, etc. For citation data, the three
years, two years, one year citation window was used for pub-
lications during 2004-11, 2012 and 2013. In addition, citations
of publications were also collected from date of publications
till the end of July 2014 for sections 4.1 and 4.10.
Literature search results
The world and India has published 89994 and 1368 publica-
tions in prostate cancer during 2004-13, which have in-
creased from 6402 and 55 publications in 2004 to 11739 and
239 publications in 2014, registering an annual average
growth rates of 7.87% and 18.77%. The cumulative growth of
world and Indian publication output in prostate cancer re-
search has increased from 37482 and 389 publications during
2004-08 to 52512 and 979 publications during 2009-13, wit-
nessing a growth rate of 40.10% and 151.67%. India’s global
publications share in prostate cancer was 1.52% during
2004-13, which increased from 1.04% during 2004-08 to
1.86% during 2009-13. The average citation per publication
registered by Indian publications in prostate cancer was 5.23
during 2004-13, which had increased from 4.91 during
2004-08 to 5.35 during 2009-13. Of the total Indian publica-
tions in prostate cancer during 2004-13, articles constituted
67.03% share, reviews (21.35%), letters (3.07%), conference
publications (2.70%), notes (2.12%), editorial (1.75%), nook
chapters (0.80%), short surveys (0.80%) and articles in press
(0.07%) Table 1.
TABLE 1: World and Indian literature in prostate cancer: Growth,






TP TC ACPP ICP %ICP
2004 6402 55 246 4.47 10 18.18
2005 7013 59 192 3.25 10 16.95
2006 7350 77 341 4.43 18 23.38
2007 8144 85 471 5.54 19 22.35
2008 8573 113 661 5.85 38 33.63
2009 9234 127 459 3.61 27 21.26
2010 9830 147 778 5.29 30 20.41
2011 10390 227 1700 7.49 64 28.19
2012 11319 239 1935 8.10 56 23.43
2013 11739 239 365 1.53 48 20.08
2004-08 37482 389 1911 4.91 95 24.42
2009-13 52512 979 5237 5.35 225 22.98
2004-13 89994 1368 7148 5.23 320 23.39
TP = Total publications; TC = Total citations; ACPP = Average
citations per publication; ICP = International collaborative
publications
Citation pattern of research output
Citations of 1368 Indian publications during 2004-13 in
prostate cancer were examined since the year of publication
till June July 2014. During this period, 14428 citations were
received by 1368 publications, leading to the average citation
per publication of 10.55. Only 28.65% of the total publica-
tions did not get any citations (zero citation) and rest of the
71.35% publications were cited one or more times. Of the
total cited publications, 3.29% publications (receiving more
than 50 citations) contributed 34.27% citations share, 4.02%
publications (received citations from 31 to 50) contributed
14.83% citations share, 17.91% publications (received cita-
tions from 11 to 30) contributed 33.28% citation share and
the rest 46.13% publications (receiving citations from 1 to
20) contributed 17.63% citations share (Table 2).












0 392 0 28.65 0.00
1-10 631 2543 46.13 17.63
11-30 245 4802 17.91 33.28
31-50 55 2139 4.02 14.83
51-100 32 1959 2.34 13.58
>100 13 2985 0.95 20.69
Total 1368 14428 100.00 100.00
* Citations are from date of publications till July 2014
Global publication share and citation impact of top 15
most productive countries
The total global research output in prostate cancer originated
in 113 countries during 2004-13. Of the 113 countries, 87
countries produced 1 to 50 publications, 10 countries from 51
to 100 publications, 11 countries from 101 to 400 publica-
tions, 2 countries from 501 to 700 publications, 2 countries
from 1401 to 1800 publications and 1 country between 4801
to 4900 publications during 2004-13.
Table 3 lists the output of top 15 most productive countries
that produced 94.80% of the global output in prostate cancer
during 2004-13. The publication share of 15 most productive
countries in prostate cancer varied from 1.37% to 41.56%,
with highest publication share (41.56%) coming from USA,
followed by UK (7.19% share), Germany (6.64% share),
Canada (5.44% share), Italy (5.08% share), Japan (5.03%
share), China (4.51% share), France (4.28% share), Australia,
Netherlands, Spain and Sweden (from 2.19 to 2.72% share),
South Korea, India and Switzerland (from 1.37 to 1.97%
share) during 2004-13. The global publication share has in-
creased by 3.23% in China, followed by Italy (1.01%), South
Korea (0.95%), India (0.83%), Australia (0.78%), Netherlands
(0.49%), Canada (0.45%), Sweden (0.32%), France (0.30%),
Switzerland (0.21%) and Spain (0.08%), as against decrease by
2.47% in USA, followed by Japan (1.05%), Germany (0.22%)
and UK (0.12%) from 2004-08 to 2009-13. Similarly, the
global publication rank has increased from 8th to 4th in case of
China and Australia (from 11th to 9th), as against decrease in
rank from 4th to 7th in case of Japan and France (from 7th to 8th)
from 2004-08 to 2009-13. The publication rank of other
countries has remained the same during this period.
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TABLE 3: Publication output, global publication share and rank of top 15 most productive countries in prostate cancer, 2003-12.
Country Number of Publications Global Publication Share Rank
2004-08 2009-13 2009-13 2004-08 2009-13 2009-13 2004-08 2009-13 2004-13
United States 16118 21287 37405 43.00 40.54 41.56 1 1 1
United Kingdom 2724 3751 6475 7.27 7.14 7.19 2 2 2
Germany 2537 3441 5978 6.77 6.55 6.64 3 3 3
Canada 1941 2958 4899 5.18 5.63 5.44 5 5 4
Italy 1682 2888 4570 4.49 5.50 5.08 6 6 5
Japan 2116 2412 4528 5.65 4.59 5.03 4 7 6
China 985 3077 4062 2.63 5.86 4.51 8 4 7
France 1538 2312 3850 4.10 4.40 4.28 7 8 8
Australia 849 1600 2449 2.27 3.05 2.72 11 9 9
Netherlands 909 1533 2442 2.43 2.92 2.71 10 10 10
Spain 947 1367 2314 2.53 2.60 2.57 9 11 11
Sweden 752 1221 1973 2.01 2.33 2.19 12 13 12
South Korea 530 1241 1771 1.41 2.36 1.97 13 12 13
India 389 979 1368 1.04 1.86 1.52 15 14 14
Switzerland 467 762 1229 1.25 1.45 1.37 14 15 15
World 37482 52512 89994
TABLE 4: International collaborative output, share and linkages of top 15 most productive countries during 2004-13.
Country Name TP ICP %CP TCL* Number of collaborative links with different countries
United States
(US)
37405 8787 23.49 9715 UK(1102), GER(1044), CAN(1457), ITL(923), JP(643), CH(1052), FR(616),
AUS(470), NET(499), SPN(407), SWD(668), SKOR(366), IND(216), SWT(252)
United Kingdom
(UK)
6475 2432 37.56 4066 USA (1102), GER (451), CAN (294), ITL (356),JP (72), CH (68), FR (386), AUS
(215), NET (352), SPN (251), SWD (339), SKOR (23), IND (29), SWT (128)
Germany (GER) 5978 2424 40.55 3897 USA (1044), UK (451), CAN (326), ITL (410), JP (54), CH (58), FR (332), AUST
(110), NET (327), SPN (187), SWD (310), SKOR (8), IND (24), SWT (256)
Canada (CAN) 4899 2313 47.21 3411 USA (1457), UK (294), GER (326), ITL (297), JP (82),CH (71), FR (225), AUS
(235), NET (157), SPN (68),  SWD (96), SKOR (12), IND (23), SWT (68)
Italy (ITL) 4570 1802 39.43 3351 USA (923), GER (410), FR (358),UK (356),CAN (297),SPN (297), NET (211),
SWD (188), SWT (169), AUS (61), JP(44), CH (17), IND (11), SKOR (9)
Japan (JP) 4528 963 21.27 1252 USA(643), CH(110), CAN(82), UK (72), GER (54), ITL(44), FR(42), SKOR(40),
AUS (39), SWD(39), NET(32), SPN(24), IND(16), SWT(15)
China (CH) 4062 1408 34.66 1577 USA(1052), JP(110), CAN (71), UK(68), GER(58), AUS(52), SWD(38), FR(34),
SKOR(33). ITL(17), NET(16), IND(13), SPN(9), SWT(6)
France (FR) 3850 1487 38.62 2839 USA(616),UK(386), ITL(358), GER(332), NET(229), CAN(225), SPN(191),
SWD(181), SWT(143), AUS(101),JP(42), CH(34), IND(12), SKOR(9)
Australia (AUS) 2449 1024 41.81 1486 USA(470), CAN(235), UK(215),GER(110), FR(101), SWD(70), ITL(61),
NET(57), CH(52), JP(39), SPN(35), SWT(16), IND(14), SKOR(11)
Netherlands
(NET)
2442 1146 46.93 2312 USA(499), UK(352), GER(327), FR(229), ITL(211), SWD(180), CAN(167),
SPN(147), SWT(82), AUS(57), JP(32),CH(16), SKOR(7), IND(6)
Spain (SPN) 2314 808 34.92 1810 USA(407), ITL (297), UK (251), FR(191), GER(187), NET(147), SWD(120),
CAN (68), SWT(63),  AUS (35), JP (24), CH (9), SKOR (7), IND (4)
Sweden (SWD) 1973 1230 62.34 2285 USA(668), UK(339), GER(310), ITL(188), FR(181),  NET(180), SPN(120),
CAN(96), AUS(70), SWT(42), JP(39), CH(38), SKOR (11), IND(3)
South Korea
(SKOR)
1771 444 25.07 542 USA(366), JP(40), CH(33),UK(23), CAN(12), AUS(11), SWD(11), ITL(9),
FR(9), GER(8), NET(7), SPN(7), IND(4), SWT(2)
India (IND) 1368 320 23.39 378 USA(216), UK(29), GER(24),CAN(23), JP(16), CH(13), FR(12), ITL(11),
NET(6), SPN(4), SKPR(4), SWD(3), SWT(3)
Switzerland
(SWT)
1229 762 62.00 1245 GER(256), USA(252), ITL(169), FR(143), UK(128), , NET(82), CAN(68),
SPN(63), SWD(42), AUS(16), JP(15), CH(6), IND(3), SKOR(2)
*TP = Total publications; ICP=International collaborative publications; TCL = Total collaborative links with top 15 most productive
countries
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2004-08 2009-13 2004-13 2004-08 2009-13 2004-13
1 USA 70 146 216 73.68 64.89 67.50
2 U.K. 8 21 29 8.42 9.33 9.06
3 Germany 7 17 24 7.37 7.56 7.50
4 Canada 5 18 23 5.26 8.00 7.19
5 Japan 5 11 16 5.26 4.89 5.00
6 Saudi Arabia 2 14 16 2.11 6.22 5.00
7 Australia 3 11 14 3.16 4.89 4.38
8 China 2 11 13 2.11 4.89 4.06
9 France 2 10 12 2.11 4.44 3.75
10 Italy 4 7 11 4.21 3.11 3.44
95 225 320
Sweden registered the highest share (62.34%) of international
collaborative publications among the top 15 countries in
prostate cancer during 2004-13, followed by Switzerland
(60.00%), Canada (47.21%), Netherlands (46.93%), Australia
(41.81%), Germany (40.55%), Italy (39.43%), France
(38.62%), UK (37.56%), Spain (34.92%), China (34.66%),
South Korea (25.70%), USA (23.49%), India (23.39%) and
Japan (21.27%). United States received the highest number
(9715) of inter-country international collaboration linkages
among the top 15 countries in prostate cancer, followed by
UK (4066 linkages), Germany (3897 linkages), Canada (3411
linkages), Italy (3351linkages), France (2839 linkages), Neth-
erlands (2312 linkages), Sweden (2285 linkages), Spain (1810
linkages), China (1577 linkages), Australia (1486 linkages),
Japan (1252 linkages), Switzerland (1245 linkages), South
Korea (542 linkages) and India (378 linkages) during 2004-13
(Table 4).
The largest number of inter-country collaborative linkages
(1457) was between USA-Canada, followed by USA-UK (1102
linkages), USA-China (1052 linkages), USA-Germany (1044
linkages), USA-Italy (923 linkages), USA-Sweden (668 link-
ages), USA-Japan (643 linkages), USA-France (616 linkages),
USA-Netherlands (499 linkages), USA-Australia (470 linkag-
es), UK-Germany (451 linkages), Germany-Italy (410 linkag-
es), USA-Spain (407 linkages), UK-France (386 linkages),
USA-South Korea (366 linkages), France-Italy (358 linkages),
UK-Italy (356 linkages), Netherlands-UK (352 linkages),
UK-Sweden (339 linkages), Germany-France (332 linkages),
Germany-Netherlands (327 linkages), Canada-Germany (326
linkages), and so on, during 2004-13 (Table 4). From the
above, we can conclude that China, Switzerland South Korea
and India have not been preferred partner for international
collaboration among the top 15 countries
International collaboration
The share of international collaborative publications in In-
dia’s total publication output in prostate cancer research was
23.39% during 2004-13, which decreased from 24.42% during
2004-08 to 22.98% during 2009-13. India has collaborated
with 72 countries in prostate cancer research during 2004-13
and the largest share (67.50%) was contributed by United
States during 2004-13, followed by UK (9.06%), Germany
(7.50%), Canada (7.19%), Japan and Saudi Arabia (5.00%
each), Australia (4.38%), China (4.06%), France (3.75%) and
Italy (3.44%) during 2004-13. The international collaborative
publications share increased by 4.11% in Saudi Arabia, fol-
lowed by China (2.78%), Canada (2.74%), France (2.33%),
Australia (1.73%). UK (0.91%) and Germany (0.19), as against
decrease by 8.79% in USA, followed by Italy (1.1%) and Japan
(0.37%) from 2004-08 to 2009-13 (Table 5).
Subject-wise distribution of research output
India’s prostate cancer research output during 2004-13 has
been published in the context of six sub-fields (as reflected in
Scopus database classification), with highest publications
share (59.50%) coming from medicine, followed by bio-
chemistry, genetics & molecular biology (40.13%), pharma-
cology, toxicology & pharmaceutics (27.63%), chemistry
(8.55% share), agricultural & biological sciences (4.31%
share) and immunology & microbiology (2.70% share).
The research activity, as reflected in activity index, has wit-
nessed increase in, pharmacology, toxicology and pharma-
ceutics, chemistry, agricultural & biological sciences and
immunology & microbiology in contrast to decrease in med-
icine and biochemistry, genetics & molecular biology from
2004-08 to 2009-13. Among these six subjects, the largest
citation impact per publication (7.47) was registered by ag-
ricultural & biological sciences, biochemistry, genetics &
molecular biology (6.71), chemistry (6.61), pharmacology,
toxicology and pharmaceutics (6.34), medicine (4.83) and
immunology & microbiology (3.89) during 2004-13 (Table 6).
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TABLE 6: Subject-wise break-up of India’s publications in prostate cancer, 2003-13.
S.N Subject Areas Number of Publications (TP)* Activity Index TC ACPP H-INDEX ICP(%ICP) % TP
2004-08 2004-08 2004-08 2004-08 2009-13 2004-13 2004-13 2004-13 2004-13 2004-13












66 312 378 61.40 115.34 2398 6.34 32 80
(21.16%)
27.63














389 979 1368 100.00 100.00
* There is a duplication of publications under various subject areas, as some journals covered are common in different subject areas
TP=Total publications; TC=Total citations; ACPP=Average citations per publication; ICP=International collaborative publications
TABLE 7: Distribution of India’s prostate cancer publications by treatment methods, 2004-13.
Treatment
methods
Number of Publications Share of Publications
2004-08 2009-13 2004-13 2004-08 2009-13 2004-13
Diagnosis 51 143 194 13.11 14.61 14.18
Screening 32 131 163 8.23 13.38 11.92
Chemotherapy 31 107 138 7.97 10.93 10.09
Radiotherapy 29 87 116 7.46 8.89 8.48
Pathology 40 69 109 10.28 7.05 7.97
Prognosis 21 83 104 5.40 8.48 7.60
Surgery 25 64 89 6.43 6.54 6.51
Genetics 29 39 68 7.46 3.98 4.97
Quality of Life 8 37 45 2.06 3.78 3.29
Epidemiology 5 13 18 1.29 1.33 1.32
Palliative care 4 4 8 1.03 0.41 0.58
Total of the country 389 979 1368
Prostate cancer publications by treatment methods
In terms of treatment methods used in prostate cancer during
2004-13, the largest publication share (14.18%) was registered
by diagnosis, followed by screening (11.92%), chemotherapy
(10.09%), radiotherapy (8.48%), pathology (7.97%), prognosis
(7.60%), surgery (6.51%), genetics (4.97%), epidemiology
(1.32%) and palliative care (0.58%) during 2004-13. The
publication share has increased by 5.15% (from 8.23% to
13.38%) in screening, followed by 3.08% ( from 5.40% to
8.48%) in prognosis, 2.96% (from 7.97% to 10.93%) in
chemotherapy, 1.72% (from 2.06% to 3.78%) in quality of
life, 1.50% (from 13.11% to 14.61%) in diagnosis, 1.43%
(from 7.46% to 8.89%) in radiotherapy, 0.11% (from 6.43% to
6.54%) in surgery and 0.04% (from 1.29% to 1.33%) in epi-
demiology, as against decrease by 3.48% (from 7.46% to
3.98%) in genetics, 3.23% (from 10.28% to 7.05%) in pa-
thology and 0.62% (from 1.03% to 0.41%) in palliative care
from 2004-08 to 2009-13 (Table 7).
Geographical distribution of research output
Among Indian states and union territories contributing to
prostate cancer research during 2004-13, the largest publica-
tion share (16.52%) comes from Delhi, followed by Maha-
rashtra (15.35%), Uttar Pradesh (15.06%), Tamil Nadu
(10.89%), Andhra Pradesh (7.38%), Karnataka (6.94%),
Chandigarh (5.12%), West Bengal (4.61%), Punjab (2.41%),
Haryana and Kerala (2.05% each), Madhya Pradesh (1.75%),
Rajasthan (1.61%) and Pondicherry (0.51%).
Together the first four states account for 57.82% share of
Indian publications in prostate cancer during 2004-13. The
share of prostate cancer publications have increased by 4.21%
(4.37% to 8.58%) in Andhra Pradesh, 1.53% (from 0.51% to
2.04%) in Rajasthan, 1.41% (from 3.60% to 5.01) in West
Bengal, 1.08% (from 6.17% to 7.25%) in Karnataka, 0.85%
(from 10.28% TO 11.13%) in Tamil Nadu and 0.35% (from
1.80% to 2.15%) in Kerala, as against decrease by 6.73% (from
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21.34% to 14.61%) in Delhi, 3.38% (from 17.48% to 14.01%)
in Uttar Pradesh, 1.90% (16.71% to 14.81%) in Maharashtra,
1.09% ( from 2.83% to 1.74%) in Haryana, 0.72% (from 1.03%
to 0.31%) in Pondicherry, 0.43% (from 2.06% to 1.63%) in
Madhya Pradesh, 0.39% (from 5.40% to 5.01%) in Chandi-
garh and 0.22% (from 2.57% to 2.35%) in Punjab from
2004-08 to 2009-13.(Table 8 )
TABLE 8: Geographical distribution of prostate cancer research

















Delhi 83 143 226 21.34 14.61 16.52
Maha-
rashtra
65 145 210 16.71 14.81 15.35
Uttar
Pradesh
68 138 206 17.48 14.10 15.06
Tamil
Nadu
40 109 149 10.28 11.13 10.89
Andhra
Pradesh
17 84 101 4.37 8.58 7.38
Karnataka 24 71 95 6.17 7.25 6.94
Chandi-
garh
21 49 70 5.40 5.01 5.12
West
Bengal
14 49 63 3.60 5.01 4.61
Punjab 10 23 33 2.57 2.35 2.41
Haryana 11 17 28 2.83 1.74 2.05
Kerala 7 21 28 1.80 2.15 2.05
Madhya
Pradesh
8 16 24 2.06 1.63 1.75
Rajasthan 2 20 22 0.51 2.04 1.61
Pondi-
cherry
4 3 7 1.03 0.31 0.51
389 979 1368
Profile of top 20 most productive organizations
The productivity of 20 most productive Indian organizations
in prostate cancer varied from 11 to 90 publications and to-
gether contributed 41.81% (572 publications) share in the
cumulative publications output of India in prostate cancer
research during 2004-13. The scientometric profile of these
20 Indian organizations is presented in Table 9. Seven or-
ganizations have registered higher publications output than
the group average of 28.60: AIIMS-New Delhi (90 publica-
tions), SGPGIMS-Lucknow (59 publications), TMC-Mumbai
(44 publications), PGIMER- Chandigarh (42 publications),
IIIM-Srinagar (39 publications), CSMUNIV- Lucknow (35
publications) and IICT-Hyderabad (34 publications). Six
organizations have registered more than the average citation
per publication (7.31) of 20 organizations: IITR-Lucknow
(18.53), SGPGIMS-Lucknow (16.19), AIIMS-New Delhi
(11.54), JNU-New Delhi (10.74), NIPER-Mohali (9.33) and
CCMB-Hyderabad (8.45) during 2004-13.
Ten organizations have registered more than the average
h-index (8.95) of all 20 organizations during 2004-13:
AIIMS-New Delhi (17), SGPGIMS-Lucknow (14), JNU-New
Delhi and University of Madras (13 each), IITR-Lucknow
(12), JNU-New Delhi, IICT-Hyderabad and IIIM-Srinagar (10
each), CDRI-Lucknow and TMH-Mumbai (9 each) during
2004-13. Eight organizations have achieved more than the
average share of international collaborative publications
(19.23%) of all 20 organizations: JNU-New Delhi (63.16%),
AMU-Aligarh (46.15%), IISc-Bangalore (33.33%),
GNDUNIV-Amritsar (30.77%), CDRI-Lucknow (29.41%),
BARC-Mumbai (25.00%), IICT- Hyderabad (23.53%) and
TMH-Mumbai (20.45%) during 2004-13.
The largest number of national collaborating linkages (15)
among the most productive  organizations were made by
Panjab University (PUNJU), Chandigarh with five organiza-
tions (PGIMER-6, AIIMS-5, IIIM-2, GNDUNIV-1 AND
NIPER-1), followed by Postgraduate Institute of Medical
Education & Research, Chandigarh with 14 linkages with 3
organizations (AIIMS-6, PUNJU-6 and NIPER-2), All India
Institute of Medical Sciences, New Delhi with 13 linkages
with 3 organizations (PGIMER-6, PUNJU-5 and JNU-2), CS
Maharaj Medical University (CSMUNIV), Lucknow with 11
linkages with 2 organizations (CDRI-8 and SGPGIMS-5),
Central Drug Research Institute, Lucknow with 8 linkages
with 3 organizations (CSMMUNIV-6, CCMB-1 and IITR-1),
Indian Institute of Chemical Technology, Hyderabad with 8
linkages with 3 organizations (CSMMUNIV-6, CCMB-1 and
IITR-1), Sanjay Gandhi Postgraduate Institute pf Medical
Education & Research, Lucknow with 7 linkages with 2 or-
ganizations (CSMMUNIV-5 and CCMB-2), Tata Memorial
Center, Mumbai with 7 linkages with 2 organizations
(CSMMUNIV-5 and CCMB-2), Guru Nanak Dev University,
Amritsar with 6 linkages with 2 organizations (IIIM-5 and
PUNJU-1), Centre for Cellular & Molecular Biology, Hyder-
abad with 5 linkages with 3 organizations (IICT-2,
SGPGIMS-2 and CDRI-1), National Institute of Pharmaceu-
tical Education & Research, Mohali with 3 linkages with 2
organizations (PGIMER-2 and PUNJU-1) and Tata Memorial
Centre, Mumbai, with 2 linkages with BARC, Mumbai.
Profile of top 19 most productive Indian authors
The top 19 most productive Indian authors have published 11
to 44 publications each and together contributed 24.05% (329
publications) share in the cumulative publications output of
India in prostate cancer research during 2004-13. The scien-
tometric profile of these 19 Indian authors is presented in
Table 10.
Six authors have registered higher publications per author
than the group average (17.32): Mittal RD (44 publications),
Saxena AK (25 publications), Gupta NP (22 publications),
Aruna Karan (22), Mandhani A (21) and Kumar R (6 publica-
tions). Eight authors have registered more than the average
citation per publication (6.43) of all 19 authors during
2003-12: Mandal RK (18.60), Singh RP (13.58), Padhye S
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(12.53), Mandal RK (9.00), Arunkumar A (7.33), Vijayababu
MR (7.29), Aruna Karan (7.14) and Kamal A (6.92) during
2004-13. Eight authors have registered more than the average
h-index (9.32) of all 19 authors during 2003-12: Mittal RD
and Aruna Karan with h-index of 14 each, followed by Vi-
jayababu MR and Shukla y (12 each), Singh RP and
Arunkumar A (11 each), Mandhani A and Padhye S (10 each).
Four authors have achieved more than the average share of
international collaborative publications (17.33%) of all 19
authors: Padhye S (100.00%), Singh RP (83.33%), Kamal A
(25.00%) and Hemal AK (25.0%)
Media of communication
The 20 most productive journals contributed from 8 to 61
papers and together contributed 24.93% share (341 papers)
to the total journal publication output in prostate cancer
during 2004-13. The publication share of these top 15 most
productive journals decreased from 27.25% to 24.00% from
2004-08 to 2009-13. Of these 20 journals, the highest citation
impact per paper of  45.89 by Cancer Research, followed by
Molecular & Cellular Biochemistry (21.11), PLOS One
(20.35), BJU International (14.56), European Journal of Me-
dicinal Chemistry (13.76), Bioorganic & Medicinal Chemis-
try Letters (12.84), Urology (6.56), Asia Pacific Journal of
Cancer Prevention (6.06), etc.
TABLE 9: Scientometric profile of top 15 most productive Indian organizations in prostate cancer, 2004-13.
S.N Name of Organization TP TC ACPP ICP %ICP HI NCL
(NO)
1 All India Institute of Medical Sci-
ences, New Delhi.
90 1039 11.54 16 17.78 17 13(3)
2 Sanjay Gandhi Postgraduate Insti-
tute of Medical Sciences, Lucknow.
59 955 16.19 4 6.78 14 7(2)
3 Tata Memorial Hospital, Mumbai 44 136 3.09 9 20.45 9 2(1)
4 Postgrduate Institute of Medical
Education & Research, Chandigarh.
42 77 1.83 7 16.67 8 14(3)
5 Indian Institute of Integrated
Medicine, Srinagar.
39 183 4.69 5 12.82 10
6 CS Maharaj Medical University,
Lucknow.
35 89 2.54 5 14.29 6 11(2)
7 Indian Institute of Chemical
Technology, Hyderabad.
34 165 4.85 8 23.53 10 8(3)
8 University of Madras. 27 160 5.93 4 14.81 13 0
9 Panjab University, Chandigarh. 27 163 6.04 5 18.52 10 15(5)
10 Christian Medical College, Vellore. 24 11 0.46 2 8.33 2 0
11 Bhabha Atomic Research Center,
Mumbai.
20 88 4.40 5 25.00 8 2(1)
12 Jawaharlal Nehru University, New
Delhi.
19 204 10.74 12 63.16 13 2(1)
13 Central Drugs Research Institute,
Lucknow.
17 110 6.47 5 29.41 9 8(3)
14 Indian Institute of Toxicological
Research, Lucknow.
15 278 18.53 2 13.33 12
15 National Institute of Pharmaceuti-
cal Education & Research, Mohali.
15 140 9.33 2 13.33 7 3(2)
16 Indian Institute of Science, Banga-
lore
15 80 5.33 5 33.33 5
17 Guru Nanak Dev University, Am-
ritsar
13 85 6.54 4 30.77 7 6(2)
18 Jawaharlal Nehru Technological
University, Hyderabad
13 33 2.54 2 15.38 4
19 Aligarh Muslim University, Ali-
garh
13 90 6.92 6 46.15 7
20 Centre for Cellular & Molecular
Biology, Hyderabad
11 93 8.45 2 18.18 8 5(3)
Total of 20 top organizations 572 4179 7.31 110 19.23 8.95
Total of the country 1368
Share of top 20 organizations in
India’s output
41.81
TP=Total publications; TC=Total citations; ACPP=Average citation per publication; ICP=International
collaborative publications; HI=h-index; NCL=National collaborative linkages
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TABLE 10: Scientometric profile of top 19 Indian authors in prostate cancer, 2004-13.
S.N Name Affiliation TP TC ACPP ICP %ICP HI
1 Mittal RD Sanjay Gandhi Postgraduate Institute of Medical Sci-
ences, Lucknow
44 243 5.52 3 6.82 14
2 Saxena AK Indian Institute of Integrated Medicine, Srinagar 25 131 5.24 4 16.00 9
3 Gupta NP All India Institute of Medical Sciences, New Delhi 22 92 4.18 2 9.09 9
4 Karan A ALM Postgraduate Institute of Basic Medical Sciences,
University of Madras, Madras
22 157 7.14 3 13.64 14
5 Mandhani A Sanjay Gandhi Postgraduate Institute of Medical Sci-
ences, Lucknow
21 73 3.48 2 9.52 10
6 Kumar R All India Institute of Medical Sciences, New Delhi 21 71 3.38 2 9.52 8
7 Seth A All India Institute of Medical Sciences, New Delhi 16 82 5.13 1 6.25 8
8 Shukla Y Indian Institute of Toxicological Research, Lucknow 15 279 18.60 2 13.33 12
9 Mandal RK Sanjay Gandhi Postgraduate Institute of Medical Sci-
ences, Lucknow
15 135 9.00 0 0.00 8
10 Padhye S University of Pune 15 188 12.53 15 100.0
0
10
11 Vijayababu MR ALM Postgraduate Institute of Basic Medical Sciences,
University of Madras, Madras
14 102 7.29 2 14.29 12
12 Goel A CS Maharaj Medical University, Lucknow 14 22 1.57 0 0.00 4
13 Jagannathan
NR
All India Institute of Medical Sciences, New Delhi 14 57 4.07 2 14.29 8
14 Singh RP Jawaharlal Nehru University New Delhi 12 163 13.58 10 83.33 11
15 Nayyar R All India Institute of Medical Sciences, New Delhi 12 39 3.25 0 0.00 6
16 Kamal A Indian Institute of Chemical Technology, Hyderabad 12 83 6.92 3 25.00 8
17 Arunkumar A ALM Postgraduate Institute of Basic Medical Sciences,
University of Madras, Madras
12 88 7.33 2 16.67 11
18 Hemal AK All India Institute of Medical Sciences, New Delhi 12 56 4.67 3 25.00 8
19 Thulkar S All India Institute of Medical Sciences, New Delhi 11 56 5.09 1 9.09 7
Total output 329 2117 6.43 57 17.33 9.32
Total output of India 1368
Share of 19 authors in India’s output 24.05
TP=Total publications; TC=Total citations; ACPP=Average citation per publication; ICP=International collaborative publications;
HI=h-index
In Summary, India has contributed 1368 publications in
prostate cancer, which has increased from 55 to 239 publica-
tions from the year 2004 to 2013, registering an annual av-
erage growth rate of 18.77%. India’s publications in prostate
cancer have registered citation impact per publication of 5.23
during 2004-13, which has increased from 4.91 during
2004-08 to 5.35 during 2009-13. India is ranked at 14th place
in global research output, with global publications share of
1.52% during 2004-13, increasing from 1.04% during 2004-08
to 1.86% during 2009-13. India’s share of international col-
laborative publications in prostate cancer was 23.39% during
2004-13, which has decreased from 24.42% to 22.98% from
2004-08 to 2009-13. Only 71.35% of the total publications
received 1 or more citations since their publications till June
2014. Of the total cited publications, 3.29% publications
contributed 34.27% citations share, 4.02% publications con-
tributed 14.83% citations share, 17.91% publications con-
tributed 33.28% citation share and the rest 46.13% publica-
tions contributed 17.63% citations share during 2004-13. In
terms of subject-wise contribution, the largest publication
share (59.50%) comes from medicine, followed by biochem-
istry, genetics & molecular biology (40.13%), pharmacology,
toxicology & pharmaceutics (27.63%), chemistry (8.55%),
agricultural &  biological sciences (4.31% share) and immu-
nology & microbiology (2.70% share)during 2004-13. The
largest citation impact per publication (7.47) was made by
agricultural & biological sciences, biochemistry, genetics &
molecular biology (6.71), chemistry (6.61), pharmacology,
toxicology and pharmaceutics (6.34), medicine (4.83) and
immunology & microbiology (3.89) during 2004-13. In terms
of treatment methods used in prostate cancer research, the
largest publications share (14.18%) comes from diagnosis,
followed by screening (11.92%), chemotherapy (10.09%),
radiotherapy (8.48%), pathology (7.97%), prognosis (7.60%),
surgery (6.51%), genetics (4.97%) during 2004-13. Delhi
among Indian states & union territories, contributed the
largest share (16.52%) to prostate cancer research, followed
by Maharashtra (15.35%), Uttar Pradesh (15.06%), Tamil
Nadu (10.89%), Andhra Pradesh (7.38%), Karnataka (6.94%),
Chandigarh (5.12%), West Bengal (4.61%), etc during
2003-12. The 20 most productive Indian organizations con-
tributing to prostate cancer research has contributed 572
publications, accounting for 41.81% share of the country’s
publication output.
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TABLE 11: Contribution and citation impact of journals where Indian scholars have contributed during 2004-13.
S.N Name of the Journal Number of Publications (TP) TC* ACPP
2004-08 2009-13 2004-13 2004-13 2004-13
1 Indian Journal of Urology 22 39 61 64 1.05
2 Asia Pacific Journal of Cancer Prevention 12 21 33 200 6.06
3 Journal of Cancer Research & Therapeutics 5 19 24 92 3.83
4 Indian Journal of Cancer 6 18 24 116 4.83
5 European Journal of Medicinal Chemistry 2 19 21 289 13.76
6 Indian Journal of Pathology & Microbiology 14 5 19 46 2.42
7 Bioorganic & Medicinal Chemistry Letters 3 16 19 244 12.84
8 PLOS One 1 16 17 346 20.35
9 International Journal of Pharmaceutical Sciences Review &
Research
0 16 16 6 0.38
10 International Journal of Pharmacy & Pharmaceutical Sciences 0 12 12 9 0.75
11 Indian Journal of Clinical Biochemistry 6 6 12 54 4.50
12 Journal of International Medical Science Academy 7 4 11 0 0.00
13 International Journal of Pharma & Biosciences 0 10 10 14 1.40
14 Molecular & Cellular Biochemistry 4 5 9 190 21.11
15 National Medical Journal of India 3 6 9 31 3.44
16 Cancer Research 8 1 9 413 45.89
17 Journal of Medical Physics 2 7 9 23 2.56
18 BJU International 6 3 9 131 14.56
19 Urology 5 4 9 59 6.56
20 Indian Journal of Medical Pediatrics & Oncology 0 8 8 23 2.88
Total of 20 journals 106 235 341 2350
Total of India in journal output 389 979 1368
Share of 20 journals in India’s journal output 27.25 24.00 24.93
TP = Total publications; TC = Total citations; ACPP = Average citation per publication
*Citations of publications are from date of publications until July 2014
The average productivity, average citation impact per publi-
cation, h-index and share of international collaborative pub-
lications of the 15 most productive Indian organizations were
26.80, 7.31, 8.95 and 19.23% during 2004-13. The 19 most
productive Indian authors contributing to prostate cancer
research has contributed 329 publications, accounting for
24.05% share of the country’s publication output. The aver-
age productivity, average citation impact per publication,
h-index and share of international collaborative publications
of the 15 most productive Indian authors were 17.32, 6.43,
9.32 and 17.33% during 2003-12.
Conclusion
In order to increase the national output and international
collaboration and improve citation impact, there is an urgent
need to increase awareness and understanding of the burden
of disease associated with prostate cancer, undertake the
evaluation of existed prostate cancer related programs and
establish a national prostate cancer program at the national
level in India. It is also important to develop a systematic
screening program for detection and diagnosis of prostate
cancer cases to be followed by evolution of suitable man-
agement strategy and more effective treatment options for
treatment of prostate cancer. There is also need to increase
funding support for research and development (R&D) and
develop training programs for concerned persons at different
levels.
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